Abstract

For more than 50 years, the elevation in intraocular pressure that can impede the administration of topical or systemic corticosteroids has been recognized. There has been increasing attention in this steroid-responsive phenomena since the identification of the myocilin gene (formerly known as the trabecular meshwork inducible glucocorticoid response or TIGR gene). In addition, the increasingly popular use of injectable intraocular steroids to treat clinically substantial subretinal fluid and macular oedema has increased the incidence. Animal studies, cell biology, molecular biology, and a better grasp of genetics have all contributed to a better understanding of the response's mechanics. The electronic MEDLINE, Embase, Cochrane, and PubMed databases were searched. Additionally, the bibliography of all relevant articles and textbooks were manually searched. To determine the link between plasma cortisol levels and steroid-induced glaucoma, plasma cortisol levels can be tested once every four hours. It can also be done on a bigger group of people. The steroid provocative test will aid in the identification of individuals who are high steroid responders in the general population. It can also be used in patients who require intravitreal triamcinolone injections. Genetic research could shed further light on the aetiology of steroid-induced glaucoma.

Key words: Clinical Analysis, Glucocorticosteroids, Glaucoma.